Aaron N. Winn
Associate Professor, University of Illinois at Chicago
Email:
Related Sites:
About Heading link
Teaching and Supervision Heading link
Ph.D. Thesis Research (PSOP 599), 8/26/2024 – 12/6/2024
Independent Study (PSOP 596), 8/26/2024 – 12/6/2024
Independent Study (PSOP 596), 1/8/2024 – 4/26/2024
Selected Grants
Understanding the Importance of Industry Relationships for Cancer Care Quality, Outcomes, and Costs, Memorial Sloan-Kettering Cancer Ctr., 8/1/2023 - 7/31/2027, Obligated Amount: $174937; Anticipated Amount: $174937
UIC Sub - Bridging Community-based Continence Promotion and Primary Care, Medical College of Wisconsin., 7/8/2023 - 1/31/2025, Obligated Amount: $10413; Anticipated Amount: $64710
Understanding and Addressing Opioid and Benzodiazepine Co-prescribing among Older Adults with Cancer, Duke University., 12/1/2022 - 11/30/2024, Obligated Amount: $4568; Anticipated Amount: $4568
Bridging Community-based Continence Promotion and Primary Care, Agency for Healthcare Research and Quality., 2/1/2022 - 1/31/2025, Obligated Amount: $3000000; No Anticipated Amount Set
Understanding and addressing health disparities in Wisconsin through statewide partnerships, Advancing Healthier Wisconsin., 7/1/2021 - 6/30/2024, Obligated Amount: $1500000; No Anticipated Amount Set
Wisconsin Exploratory Center for Interdisciplinary Research in Benign Urology. Project Title: Improving Lower Urinary Tract Symptoms through Interdisciplinary Research and Collaboration between Primary and Specialty Care, National Institute of Diabetes and Digestive and Kidney Diseases., 9/15/2020 - 6/30/2022, Obligated Amount: $624000; No Anticipated Amount Set
The Cure Sickle Cell Initiative Economic Analysis: An Evaluation of the Costs of Sickle Cell Disease and Potential Health Plan Budget Impacts of Gene Therapy as a New Treatment Option, National Heart, Lung, and Blood Institute., 7/1/2019 - 6/30/2023, Obligated Amount: $727500; No Anticipated Amount Set
Predicting and Reducing Future Health Disparities for U.S. Adults with Diabetes, National Institute on Minority Health and Health Disparities., 9/18/2018 - 4/30/2022, Obligated Amount: $1622438; No Anticipated Amount Set
Using Big Data Informatics to Improve Care of Women with Advance Breast Cancer, Clinical and Translational Research Institute, Medical College of Wisconsin., 8/1/2018 - 7/31/2020, Obligated Amount: $250000; No Anticipated Amount Set
Stopping Tyrosine Kinase Inhibitors in CML Patients (Stop-TKIs), National Cancer Institute., 9/14/2014 - 8/31/2019, Obligated Amount: $3345984; No Anticipated Amount Set
Selected Publications
Check, Devon, O’Regan, Amy, Des Marais, Andrea, Lee, Jeehye Rose, Merlin, Jessica, Cohen, Harvey Jay, McDermott, Cara L, Winn, Aaron N. (2024). Opioid and benzodiazepine prescribing in cancer: Current practices and future opportunities for mitigating potential risks.. Journal of Clinical Oncology, 20, (10_suppl), 299-299. doi:10.1200/op.2024.20.10_suppl.299.
Neuner, Joan, Schmitt, Emily, Winn, Aaron, Davidson, Emily, O’Connor, Robert C, Marowski, Sarah, Luebke, Marie, Balza, Joanna, Attewell, Madeline, Flynn, Kathryn E. (2024). Urinary Incontinence Medications: Patient-Initiated Concerns in Primary Care.. Urogynecology. doi:10.1097/spv.0000000000001540.
Mitchell, Aaron P, Kinlaw, Alan C, Peacock-Hinton, Sharon, Dusetzina, Stacie B, Winn, Aaron N, Sanoff, Hanna K, Lund, Jennifer L. (2024). Commercial Versus Medicaid Insurance and Use of High-Priced Anticancer Treatments. The Oncologist, 29, (6), 527-533. doi:10.1093/oncolo/oyae035.
Basu, Anirban, Winn, Aaron N, Johnson, Kate M, Jiao, Boshen, Devine, Beth, Hankins, Jane S, Arnold, Staci D, Bender, MA, Ramsey, Scott D. (2024). Gene Therapy Versus Common Care for Eligible Individuals With Sickle Cell Disease in the United States : A Cost-Effectiveness Analysis.. Annals of Internal Medicine, 177, (2), 155-164. doi:10.7326/m23-1520.
Winn, Aaron N, Atallah, Ehab, Cortes, Jorge, Deininger, Michael WN, Kota, Vamsi, Larson, Richard A, Moore, Joseph O, Mauro, Michael J, Oehler, Vivian G, Pinilla-Ibarz, Javier, Radich, Jerald P, Shah, Neil P, Thompson, James E, Flynn, Kathryn E. (2023). Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia. JAMA Network Open, 6, (12), e2347950. doi:10.1001/jamanetworkopen.2023.47950.
Laiteerapong, Neda, Alexander, Jason, Philipson, Louis, Winn, Aaron N, Huang, Elbert S. (2023). First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.. Annals of Internal Medicine, 176, (4), el230007. doi:10.7326/l23-0007.
Gopalan, Anjali, Winn, Aaron N, Karter, Andrew J, Laiteerapong, Neda. (2023). Racial and Ethnic Differences in Medication Initiation Among Adults Newly Diagnosed with Type 2 Diabetes. Journal of General Internal Medicine, 38, (4), 994-1000. doi:10.1007/s11606-022-07746-4.
Winn, Aaron, Basu, Anirban, Ramsey, Scott D. (2023). A Framework for a Health Economic Evaluation Model for Patients with Sickle Cell Disease to Estimate the Value of New Treatments in the United States of America. PharmacoEconomics – Open, 7, (2), 313-320. doi:10.1007/s41669-023-00390-6.
Centor, Robert M, Laiteerapong, Neda, Winn, Aaron N. (2023). Web Exclusive. Annals On Call – First-Line Drug Therapy for Type 2 Diabetes.. Annals of Internal Medicine, 176, (2), ea220004. doi:10.7326/a22-0004.
Education
Degrees:
PhD, University of North Carolina at Chapel Hill, United States, 2017
MPP, University of Chicago, United States, 2009
BS, University of Illinois at Chicago, United States, 2007